Clin Osteol 2026; 31(2): 76-77 | DOI: 10.36290/clo.2026.010

Progestin only contraception and bone healthMain theme

Vlasta Dvořáková
Katedra zdravotnických studií, VŠPJ, Jihlava

Progestin only contraception is often chosen for women with a higher cardiovascular risk. The intrauterine system with levonorgestrel is completely neutral to bone metabolism. Progestin only pills with desogestrel or drospirenone also have no negative effect on bone health. In contrast the use of depot medroxyprogesterone acetate reduces bone mineral density.

Keywords: bone mineral density, LNG-IUS, depot medroxyprogesterone acetate, progestin only pills, desogestrel, drospirenone.

Accepted: June 12, 2026; Published: July 1, 2026  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Dvořáková V. Progestin only contraception and bone health. Clinical Osteology. 2026;31(2):76-77. doi: 10.36290/clo.2026.010.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Purchase PDF - 50 CZK
    will be unlocked 1.7.2027

    References

    1. Fait T. Využití nitroděložního systému s levonorgestrelem v perimenopauze. Čes Gynek. 2024;89(2):156-159. Go to original source...
    2. Čepický P, Cibula D, Dvořák K, et al. Doporučení k předpisu gestagenní kontracepce. Aktualizace 2006. Čes Gynek. 2006;71(5):421-423.
    3. Fait T. Antikoncepce. 4. vyd. Praha: Maxdorf; 2023. 150 s.
    4. Black A, Guilbert Q, Costescu D, et al. Canadian contraception consensus (Part 3 of 4): Chapter 7 - Intrauterine contraception. J Obstet Gynaecol Can. 2016;38(2):182-222. Go to original source...
    5. Mansour D. The benefits and risks of using a levonorgestrel releasing intrauterine system for contraception. Contraception. 2012;85(3):224-234. Go to original source...
    6. Cundy T, Evans M, Roberts H. Bone density in women receiving depot medroxyprogesterone acetate for contraception. BMJ. 1991;303(6793):13-16. Go to original source...
    7. Cundy T, Ames R, Horne A, et al. A randomized controlled trial of estrogen replacement therapy in long-term users of depot medroxyprogesterone acetate. J Clin Endocrinol Metab. 2003;88(1):78-81. Go to original source...
    8. Walsh JS, Eastell R, Peel NF. Effects of depot medroxyprogesterone acetate on bone density and bone metabolism before and after peak bone mass: a case-control study. J Clin Endocrinol Metab. 2008;93(4):1317-1323. Go to original source...
    9. Ott SM, Scholes D, Lacroix AZ, et al. Effects of contraceptive use on bone biochemical markers in young women. J Clin Endocrinol Metab. 2001;86(1):179-185. Go to original source...
    10. Kyvernitakis I, Kostev K, Nassour T, et al. The impact of depot medroxyprogesterone acetate on fracture risk: a case-control study from the UK. Osteoporos Int. 2017;28(1):291-297. Go to original source...
    11. Vestergaard P, Rejnmark L, Mosekilde L. Oral contraceptive use and risk of fracture. Contraception. 2006;73(6):571-576. Go to original source...
    12. Meier C, Brauchli YB, Jick SS, et al. Use of depot medroxyprogesterone acetate and fracture risk. J Clin Endocrinol Metab. 2010;95(11):4909-4916. Go to original source...
    13. Cromer BA, Blair JM, Mahan JD, et al. A prospective comparison of bone density in adolescent girls receiving depot medroxyprogesterone acetate, levonorgestrel, or oral contraceptives. J Pediatr. 1996;129(5):671-676. Go to original source...
    14. Miller L, Patton DL, Meier A, et al. Depot medroxyprogesterone-induced hypoestrogenism and changes in vaginal flora and epithelium. Obstet Gynecol. 2000;96(3):431-439. Go to original source...
    15. Thijssen JH. Long-term effects of progestins on bone quality and fractures. Gynecol Endocrinol. 2007;23(Suppl 1):45-52. Go to original source...
    16. Rice CF, Killick SR, Dieben T, et al. A comparison of the inhibition of ovulation achieved by desogestrel 75 mg and levonorgestrel 30 mg daily. Hum Reprod. 1999;14(4):982-985. Go to original source...
    17. Fuhrmann U, Krattenmacher R, Slater EP, et al. The novel progestin drospirenone and its natural counterpart progesterone: biochemical profile and antiandrogenic potential. Contraception. 1996;54(4):243-251. Go to original source...
    18. Duijkers IJM, Herger-Mahn D, Drouin D, et al. A randomised study comparing the effect on ovarian activity of a progestogen-only pill (POP) containing desogestrel and a new POP containing drospirenone in a 24/4 regimen. Eur J Contracept Reprod Health Care. 2015;20(6):419-427. Go to original source...
    19. Doran PM, Riggs BL, Atkinson EJ, et al. Effects of raloxifene, a selective estrogen receptor modulator, on bone turnover markers and serum sex steroid and lipid levels in elderly men. J Bone Miner Res. 2001;16(11):2118-2125. Go to original source...

    Return to the content


    Clinical Osteology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.